National Conference on Biosimilars Quality

Exam-Focused Notes on the National Conference on Biosimilars Quality and Safety

Event Overview:

• Organizer: Indian Pharmacopoeia Commission (IPC)
• Date: September 10-11, 2026
• Location: Center for Cellular and Molecular Platforms (C-CAMP), Bengaluru
• Participants: 160 stakeholders from regulatory authorities, industry, academia, and research organizations.

Objectives:

• To strengthen India’s biopharmaceutical ecosystem under the BioPharma Shakti Vision, focusing on innovation, self-reliance, quality, and global competitiveness.

Key Highlights:

• Introduction of Indian Pharmacopoeia Reference Substance (IPRS) for Enoxaparin Sodium, a low molecular weight heparin used extensively in thromboembolic disorder prevention and treatment.
• The IPRS serves as a certified reference material for bioassays, ensuring accurate, consistent, and comparable evaluations of its biological activity.

Scientific and Regulatory Discussions:

• Conference addressed major scientific and regulatory challenges in the development, assessment, and safety of biosimilars.
• Emphasis on:
  • Pharmacopoeial standards
  • Key quality attributes
  • Analytical characterization
  • Comparability assessment
  • Immunogenicity and drug vigilance
  • Evolving regulatory expectations

Significance of the Conference:

• Enhances India’s indigenous pharmaceutical quality infrastructure, contributing to the Atmanirbhar Bharat (Self-reliant India) vision.
• Reinforces the importance of collaboration among regulatory authorities, pharmacopoeial institutions, industry, academia, and research organizations for a robust biosimilars ecosystem.

Keynote Insights:

• Dr. V. Kalaiselvan, Secretary and Scientific Director, IPC, highlighted:
  • The necessity of strengthening pharmacopoeial standards and reliable analytical evaluations.
  • The importance of regulatory cooperation and aligning Indian systems with evolving global regulatory expectations to promote biopharmaceutical innovation.

Technical Sessions:

• Experts from IPC, SLA, WHO, USP, NIB, IDM, BIRAC, C-CAMP, and leading biopharmaceutical organizations presented on:
  • Pharmacopoeial standard-setting
  • Regulatory science
  • Analytical development
  • Safety monitoring
  • Innovations in biological medicines

Panel Discussions:

• Focused on measures to fortify India’s biosimilar ecosystem, addressing:
  • Quality assurance
  • Analytical and regulatory capabilities
  • Scientific capacity
  • Coordination with changing national and global regulatory expectations

Poster Presentations:

• Researchers and industry professionals shared scientific work and experiences related to biosimilars.

Conclusion:

• The conference aimed to promote harmonized standards in the biopharmaceutical sector, enhancing quality, safety, innovation, and regulatory excellence.
• IPC's commitment to strengthening India’s pharmaceutical and biopharmaceutical quality infrastructure and fostering innovation through collaboration among stakeholders was reiterated.

Implications:

• The outcomes of the conference are expected to have a lasting impact on the development of biosimilars in India, facilitating adherence to international standards and enhancing the global competitiveness of Indian biopharmaceutical products.